139124 - Type 2 diabetes and CVD: managing the risk - Clinical Audit
- : Online
This Clinical e-Audit will address the management of patients with type 2 diabetes and cardiovascular disease (CVD). It has a focus on the pharmacological management of CV risk factors as well as differentiating between second- and third-line blood glucose-lowering medicines for patients with CVD based on both medicine and patient factors.Relevance to General Practice
Approximately one third of Australians with type 2 diabetes also have established CVD. Atherosclerotic CVD is the leading cause of morbidity and mortality for patients with type 2 diabetes, and they typically experience atherosclerotic CVD earlier and with greater severity than people without type 2 diabetes. Globally, 50% of all deaths related to diabetes are attributable to CVD. Management of cardiovascular risk factors is therefore especially important in patients with diabetes.
Having a combination of CVD and diabetes significantly increases the risk of death. A recent study showed that having diabetes or history of stroke or history of myocardial infarction increases the risk of all-cause mortality approximately two times. The study also showed that having any of two of these risk factors together is associated with an approximate four times increased risk, and having all three risk factors is associated with an approximate 7 times increase in risk of all-cause mortality.